INDUSTRIALISATION
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK
Subscribe
INDUSTRIALISATION
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK
SEARCH
SEARCH
advanced search
PULMONARY
SUSTAINABILITY
Andy Burns
Kindeva
A BREATH OF FRESH AIR: PHARMA’S PUSH FOR SUSTAINABLE pMDIs
Andy Burns considers the driving factors for the transition to more sustainable propellants, as well as explaining the benefits and challenges of these next-generation propellants in terms of compatibility, performance, safety and global warming potential.
SUSTAINABILITY
Simon Gardner
Bespak
SCALING LOW-CARBON pMDI PRODUCTION WITHOUT DISRUPTING PATIENT ACCESS
Simon Gardner looks at how the pharmaceutical industry is scaling up production of low-carbon pressurised metered dose inhalers to cut emissions without disrupting patient care. The article considers the challenges faced by the industry, as well as the role of CDMOs in creating sustainable, scalable solutions.
INDUSTRIALISATION
Louise Righton
Bespak
SHORTENING AND DECARBONISING THE INHALATION SUPPLY CHAIN
Louise Righton examines the potential for reducing emissions across the pMDI supply chain, considering the localisation of suppliers to shorten supply chains as well as strong partnerships for developing novel, low-carbon alternatives to current high-emission pMDI manufacturing processes.
INTERVIEW
Brian Thompson
Phillips Medisize
Interview: Phillips Medisize Grows its Capabilities with Vectura
In this exclusive interview with ONdrugDelivery’s Guy Furness, Brian Thompson and Dave Thoreson discuss Phillips Medisize’s expanded capabilities as a result of its recent acquisition of Vectura, bringing extensive expertise and experience in the inhalation sector within the global CDMO. The discussion covers how Phillips Medisize organises its global operations, the opportunities that the acquisition of Vectura represents and where the company goes next.
INTERVIEW
Chris Baron
Aptar Pharma
The Transition to Lower-Global-Warming-Potential Propellants in pMDIs
Aptar Pharma’s Chris Baron discusses how the company has developed a new metering valve technology platform – ZEN30 Futurity™ – that is compatible with leading lower-GWP propellants. By collaborating with drug developers, regulators and the pMDI supply chain, Aptar Pharma aims to support the reduction of the CO
2
footprint of pMDIs while ensuring that the pharmaceutical industry’s strict regulatory requirements are met or exceeded.
PULMONARY
Jonathan Mulpas
Aptar Pharma
THE POWER OF PULMONARY: ADVANCES IN INHALED DRUG DELIVERY EXPAND RESPIRATORY TREATMENT OPTIONS
Jonathan Mulpas discusses how advanced inhaled drug delivery devices, such as dry powder inhalers and non-propellant liquid inhalers, can meet currently unmet needs in the inhalation space, focusing on devices that Aptar and its partners are developing to realise this potential and the expertise that Aptar can offer in this area.
EXPERT VIEW
Dr Heather Jameson
BLISTERS, BONDS AND BIOLOGICS: HOW TO ACHIEVE STABILITY OF DRY POWDER BIOLOGICS
Heather Jameson and Dave Farrow cover the challenging formulation science required to develop a viable dry powder aerosol and examine the inhaler device requirements necessary to protect the formulation throughout its shelf life while also ensuring consistent, high-performance delivery.
EXPERT VIEW
Kamaal de Silva
SHIELDED THERAPEUTICS: COULD POLYMERIC NANOPARTICLES SAFEGUARD A NEW GENERATION OF INHALED DRUGS?
Kamaal de Silva and Ethan Miller provide an overview of the benefits of polymeric nanoparticles in pulmonary drug delivery and their potential to overcome key challenges in respiratory medicine, while summarising the range of pulmonary delivery devices that could benefit from their use.
PULMONARY
Dr Clair Brooks
Copley Scientific
DEVELOPING ROBUST ORALLY INHALED PRODUCTS TO ACHIEVE BETTER PATIENT OUTCOMES
Clair Brooks looks at some of the in-use issues and patient effects that good design of devices for orally inhaled drug products can address within the context of regulatory requirements for the demonstration of robustness.
PULMONARY
Dr Alan Watts
Catalent Pharma Solutions
MANUFACTURE OF MOISTURE-SENSITIVE POWDERS FOR INHALATION
Alan Watts, Yusuf Ahmed and Gabriela Dujovny discuss manufacturing methods for inhalation powders and explain how moisture protection is an essential consideration throughout the manufacturing process.
RESPIRATORY
Dr Philippe Rogueda
Merxin Ltd
TRANSFORMING MENTAL HEALTHCARE: THE RISE OF INHALABLE PSYCHEDELICS?
Philippe Rogueda discusses how inhaled psychedelic therapies are emerging as a potential game-changer in mental health due to their fast onset and precise dosing, and how their potential has resulted in a growing pipeline of therapies, paving the way for a new era in mental healthcare.
PULMONARY
Dr Carolina Dantas
Pulmotree Medical
REALISTIC BREATHING PROFILES IN IN SILICO MODELS: A PARTNERSHIP APPROACH
Carolina Dantas, Ulf Krueger and Howard Burnett discuss the critical need for precision when delivering biologics to the lungs, how PULMOTREE’s Kolibri is able to achieve this using guided breathing, and how the use of realistic breathing profiles can improve outcomes and decrease risk with in vitro and in silico testing.
CONFERENCE SHOWCASE
CONFERENCE PREVIEW: SMI.LONDON
Join colleagues from across the inhalation space at SMI.London 2025, the only conference dedicated to soft mist inhalers (SMIs) worldwide. The event will take place on Wednesday, June 25, 2025, at the Pullman London St Pancras, hosted by Merxin.
PULMONARY
Dr Clair Brooks
Copley Scientific
CASCADE IMPACTOR METRICS: EXPLORING NEW GUIDANCE ON DATA ANALYSIS
Clair Brooks, examines the parameters used to quantify and compare the aerodynamic particle size distribution metrics of orally inhaled drug products and methods for calculation, including those laid out in the new USP <1604>, with reference to both “standard” and efficient data analysis metrics to elucidate current debate and establish sufficient understanding for the effective day-to-day application of these methods.
SUSTAINABILITY
Ross Errington
Bespak
REFORMULATING pMDIS WITH NEXT-GENERATION SUSTAINABLE PROPELLANTS
Ross Errington and Simon Gardner, discuss sustainability and the reformulation of pMDIs with low-GWP propellants.
PULMONARY
Andrea Cusack
Nebu~Flow
INNOVATIVE ACOUSTIC NEBULISER TECHNOLOGY
Andrea Cusack, Elijah Nazarzadeh and John Pritchard share insights into the company’s innovative nebuliser platform, designed to overcome the technical restrictions of current technologies that limit the delivery of advanced medicines to the lungs. They also share an update on the development of new digital features for the Nebu-Flow product range.
INTERVIEW
Julien Storz
Aptar Pharma
INTERVIEW: PUREHALE
®
AND THE FUTURE OF FINE MIST DISPENSERS FOR UPPER AIRWAY TREATMENTS
Julien Storz and Giulia Mueller discuss the latest trends and treatment options available for upper airway conditions, along with the many benefits offered by Aptar Pharma’s advanced PureHale
®
systems to manufacturers.
EXPERT VIEW
Mark Parry
TRACE ANALYTICAL CONSIDERATIONS WHEN REFORMULATING pMDIS WITH NEXT-GENERATION LOW-GWP PROPELLANT SYSTEMS
Mark Parry, John McLaughlin and Tino Otte discuss the necessary studies required to understand the nitrosamine formation and leachables profiles of new pMDI propellants with lower global warming potentials as part of the pharmaceutical industry’s drive to reduce its emissions and environmental impact.
RESPIRATORY
Dr Marie-Christine Klein
URSATEC
BREEASE – DESIGNED TO ALLEVIATE BREATHING FOR INFANTS AND TODDLERS
Marie-Christine Klein, Christian Weyler and Dr Fredrik Bokvist, discuss the effects of air pollution on health – and how the Breease pacifier could help babies and young children.
EXPERT VIEW
David Webster
ENVIRONMENTAL BENEFITS OF BEDSIDE IONIC NITRIC OXIDE GENERATION
David Webster and Mark Rimkus consider the environmental impact of traditional high-pressure storage systems for nitric oxide and highlight the benefits associated with bedside ionic generation.
PULMONARY
Edgar Hernan Cuevas Brun
HCmed Innovations
IMPROVING AEROSOL DELIVERY: NANOSUSPENSION & MESH TECHNOLOGY
Edgar Hernan Cuevas Brun and Yuchi Chen, discuss how the combination of Formosa’s APNT formulation technology and HCmed’s AdheResp smart breath-actuated mesh nebuliser can work together to offer significant benefits to the aerosolisation of difficult solution-based formulations for inhalation.
SUSTAINABILITY
Nick Smalley
Kindeva
THE pMDI DILEMMA: MANAGING PATIENT NEEDS, HEALTH AND THE PLANET
Nick Smalley discusses the balancing act involved in meeting patients’ therapeutic needs while protecting the planet when it comes to pMDI development.
INTERVIEW
Alastair Willoughby
Team Consulting
Pharmapack Preview: An INTERVIEW with ALASTAIR WILLOUGHBY
CPHI Milan this year included a key discussion led by Team Consulting’s Alastair Willoughby on “Understanding the Problem of Decarbonisation in Drug Delivery”; one of the industry’s critical challenges. These themes will be discussed in greater depth at Pharmapack Europe in Paris in January.
INTERVIEW
Louise Righton
Bespak
Interview with Bespak’s Louise Righton & Benedicta Bakpa
An increasing global incidence of respiratory diseases, such as asthma and COPD, is driving demand for therapies. Simultaneously, greenhouse gas emissions continue to rise, so the pharma industry must consider how to produce much-needed nasally delivered and orally inhaled medicines whilst minimising environmental impact. Louise Righton and Benedicta Bakpa discuss the many different aspects involved in driving sustainability in inhaled drug delivery – and the next steps.
Prev
1
2
3
4
…
14
Next
Top
